SCHEMBL14830567

SCHEMBL14830567

CCCCCCCCCCCCC[C@H](O)C[C@H](O)[C@@H](C)N(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 3/20 0.53
GPR84 Q9NQS5 8/20 0.43
FFAR1 O14842 2/20 0.42
FFAR4 Q5NUL3 1/20 0.42
CYP2D6 P10635 2/20 0.39
GMNN O75496 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
THPO P40225 1/20 0.39
MTOR P42345 1/20 0.39
BLM P54132 1/20 0.39
KDM4E B2RXH2 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAPT P10636 1/20 0.39
CETP P11597 1/20 0.39
HTT P42858 1/20 0.39
UBE2N P61088 1/20 0.39
PSMD14 O00487 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14830334 1.00 SPHK1 (0.53) SPHK1GPR84FFAR1FFAR4CYP2D6
SCHEMBL14831503 1.00 SPHK1 (0.53) SPHK1GPR84FFAR1FFAR4CYP2D6
SCHEMBL14838294 1.00 SPHK1 (0.53) SPHK1GPR84FFAR1FFAR4CYP2D6
SCHEMBL5275864 0.84 SPHK1 (0.59) SPHK1GPR84FFAR1CYP2D6GMNN
SCHEMBL15935871 0.84 SPHK1 (0.59) SPHK1GPR84FFAR1CYP2D6GMNN
SCHEMBL1553302 0.84 SPHK1 (0.59) SPHK1GPR84FFAR1CYP2D6GMNN
SCHEMBL31362673 0.77 GPR84 (0.40) SPHK1GPR84FFAR1FFAR4CYP2D6
SCHEMBL23092219 0.77 GPR84 (0.58) SPHK1GPR84FFAR1FFAR4CYP2D6
SCHEMBL3356583 0.77 GPR84 (0.58) SPHK1GPR84FFAR1FFAR4CYP2D6
SCHEMBL11200396 0.77 GPR84 (0.58) SPHK1GPR84FFAR1FFAR4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140309275-A1 Sphingosine Analogs, Compositions, and Methods Related Thereto UNIV EMORY (US) 2014-10-16 US claimed
EP-2760820-A2 SPHINGOSINE ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO Emory University (US) 2014-08-06 EP claimed
WO-2013049280-A2 SPHINGOSINE ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO EMORY UNIVERSITY (US) 2013-04-04 WO claimed
EP-3448392-B1 ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO UNIV EMORY (US) 2026-05-13 EP disclosed
US-20260102422-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO UNIV EMORY (US) 2026-04-16 US disclosed
CN-109689063-B Alkyne-containing nucleotide and nucleoside therapeutic compositions and related uses thereof 埃默里大学 2026-02-27 CN disclosed
US-20260053838-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDES AND NUCLEOSIDES FOR TREATING VIRAL INFECTIONS UNIV EMORY (US) 2026-02-26 US disclosed
US-12551497-B2 N4-hydroxycytidine and derivatives and anti-viral uses related thereto EMORY UNIVERSITY (US) 2026-02-17 US disclosed
WO-2025235664-A1 PURINE NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2025-11-13 WO disclosed
US-12414961-B2 Substituted nucleosides and nucleotides for treating viral infections EMORY UNIVERSITY (US) 2025-09-16 US disclosed
US-20250281519-A1 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO EMORY UNIVERSITY 2025-09-11 US disclosed
WO-2016145142-A1 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTICS COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2016-09-15 WO disclosed
US-20160220595-A1 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO DEFENSE THREAT REDUCTION AGENCY, US DOD 2016-08-04 US disclosed
EP-3043803-A1 NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO Emory University (US) 2016-07-20 EP disclosed
WO-2016106050-A1 N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO EMORY UNIVERSITY (US) 2016-06-30 WO disclosed
WO-2015038596-A1 NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2015-03-19 WO disclosed
US-20140309275-A1 Sphingosine Analogs, Compositions, and Methods Related Thereto UNIV EMORY (US) 2014-10-16 US disclosed
WO-2014124430-A1 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2014-08-14 WO disclosed
EP-2760820-A2 SPHINGOSINE ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO Emory University (US) 2014-08-06 EP disclosed
WO-2013049280-A2 SPHINGOSINE ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO EMORY UNIVERSITY (US) 2013-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160220595-A1 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO PNP, NTPCR, TYMP SPHK1 1334/4885GPR84 2999/4885FFAR1 3566/4885
US-20260102422-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO SARS1, ITK, SLC43A1 SPHK1 694/4885GPR84 3811/4885FFAR1 482/4885
US-20260053838-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDES AND NUCLEOSIDES FOR TREATING VIRAL INFECTIONS DCTD, RNMT, NSUN2 SPHK1 1036/4885GPR84 3434/4885FFAR1 903/4885
US-20250281519-A1 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO NTPCR, TYMP, MTAP SPHK1 2264/4885GPR84 4043/4885FFAR1 3784/4885
US-12551497-B2 N4-hydroxycytidine and derivatives and anti-viral uses related thereto NSUN2, MTAP, NSUN3 SPHK1 3182/4885GPR84 3841/4885FFAR1 3609/4885
US-12414961-B2 Substituted nucleosides and nucleotides for treating viral infections PNP, NTPCR, TYMP SPHK1 1485/4885GPR84 1625/4885FFAR1 3069/4885
US-20140309275-A1 Sphingosine Analogs, Compositions, and Methods Related Thereto SPHK1, S1PR1, S1PR2 SPHK1 1/4885GPR84 1521/4885FFAR1 755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.